Enzymatic barriers to peptide and protein absorption
- PMID: 3052875
Enzymatic barriers to peptide and protein absorption
Abstract
Continuing advances in biotechnology promise to provide a large number of peptides and proteins that would significantly expand the range of pharmaceuticals to treat diseases now poorly controlled. Even at this early stage, it is clear that the success of these entities as drugs of the future would depend, at least in part, on the success in overcoming the obstacles in their delivery. Chief among these are the ubiquitous enzymatic barriers. These include the site of administration, where the peptide is placed, the vascular endothelium that peptides must cross to enter the circulation, the blood that distributes the peptide to its target site, and the liver and kidneys where the peptide is metabolized and eliminated, respectively. The review examines: (1) the nature and efficiency of the enzymatic barriers in degrading peptides and proteins at various absorption sites, and (2) the strategies that can be used to perturb these barriers. These sites include the subcutaneous and intramuscular spaces and the intestinal, nasal, buccal, rectal, vaginal, and ocular surfaces.
Similar articles
-
Enzymatic barriers for GI peptide and protein delivery.Crit Rev Ther Drug Carrier Syst. 1994;11(2-3):61-95. Crit Rev Ther Drug Carrier Syst. 1994. PMID: 7600588 Review.
-
Recent progress in protein and peptide delivery by noninvasive routes.Crit Rev Ther Drug Carrier Syst. 1991;8(4):331-94. Crit Rev Ther Drug Carrier Syst. 1991. PMID: 1769066 Review.
-
Emerging strategies for the transdermal delivery of peptide and protein drugs.Expert Opin Drug Deliv. 2005 May;2(3):533-48. doi: 10.1517/17425247.2.3.533. Expert Opin Drug Deliv. 2005. PMID: 16296773 Review.
-
Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine.Crit Rev Ther Drug Carrier Syst. 1990;7(1):35-97. Crit Rev Ther Drug Carrier Syst. 1990. PMID: 2257636 Review.
-
Alternative delivery systems for peptides and proteins as drugs.Crit Rev Ther Drug Carrier Syst. 1988;5(2):99-139. Crit Rev Ther Drug Carrier Syst. 1988. PMID: 3052876 Review.
Cited by
-
Transport of peptide and protein drugs across biological membranes.Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):83-93. doi: 10.1007/BF03190191. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2200688 Review.
-
Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.Pharm Res. 1999 Jan;16(1):16-23. doi: 10.1023/a:1018802324759. Pharm Res. 1999. PMID: 9950273
-
Intestinal absorption of peptides and peptide analogues: implications of fasting pancreatic serine protease levels and pH on the extent of oral absorption in dogs and humans.Pharm Res. 1992 Mar;9(3):320-5. doi: 10.1023/a:1015830600227. Pharm Res. 1992. PMID: 1614964
-
Oral controlled release technology for peptides: status and future prospects.Pharm Res. 1996 Dec;13(12):1760-4. doi: 10.1023/a:1016008419367. Pharm Res. 1996. PMID: 8987068 Review.
-
Oral delivery of biologically active parathyroid hormone.Pharm Res. 2001 Jul;18(7):964-70. doi: 10.1023/a:1010936227570. Pharm Res. 2001. PMID: 11496956
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources